Arkis BioSciences’ new CerebroFlo™ EVD catheter garners promising clinical feedback with its introduction across the U.S. Healthcare market. Read more in the press release.
- Healthcare Professionals
- Healthcare Professionals
Arkis BioSciences News
Med Device Online’s editor Bob Marshall examines the methodology of product development at Arkis BioSciences, and how Arkis is addressing unmet clinical needs.
The Knoxville Business Journal published the following announcement of the grand opening for Arkis BioSciences at the new UT Innovation Campus, adjacent to the Joint Institute for Advanced Materials.
Technovation.biz published coverage today of the progress achieved by Arkis Biosciences.
Arkis BioSciences was proud to announce our Grand Opening this morning at the Cherokee Farm Innovation Campus, a new high-tech facility at the University of Tennessee’s research and development campus, featuring the Joint Institute for Advanced Materials.
Arkis BioSciences is launching the CerebroFlo™ EVD Catheter with Endexo® Technology at the 2017 Congress of Neurological Surgeons, booth 747. Demonstrations are available at the booth for the Single Pass Tunneling Guidewire®, the Subcutaneous Guidewire™, and the CerebroFlo EVD Catheter.
Interface Biologics Inc. (“IBI”), a privately held, commercial stage company developing innovative material science technologies that save lives and improve patient outcomes, is pleased to announce that Arkis BioSciences® has received 510(k) clearance from U.S. Food and Drug Administration (FDA) for its exclusive CerebroFlo™ EVD Catheter with IBI’s Endexo® technology.
Arkis BioSciences, a leading innovator in minimally invasive surgical instrumentation, has obtained FDA clearance of its new external ventricular drainage catheter, CerebroFlo™. The CerebroFlo catheter has demonstrated a 99% reduction in thrombus accumulation in-vitro, and is indicated for temporary use in patients with elevated intracranial pressure, intraventricular hemorrhage, or hydrocephalic shunt infections. Arkis will debut […]
Arkis is honored to have been chosen as the Top Innovator at the 2017 NY Venture Summit, July 18-19th, 2017. Be sure to visit us in the Big Apple and learn the latest news as Arkis continues to roll out its product portfolio advancing treatments for intracranial hypertension.
Arkis BioSciences exhibits new Subcutaneous GuidewireTM, adding to its minimally invasive product line. Please visit the team now at booth 2047 of the AANS conference in Los Angeles to see the latest additions to the surgical portfolio, and receive an update on our new SureFloTM EVD catheters with Endexo® technology.
Advancing medical technology worldwide to improve the lives of people suffering from intracranial hypertension.